Breakthrough Therapy (BT) Designation Market Report

Japan Breakthrough Therapy (BT) Designation Market Professional Research Report 2014-2026, Segmented by Players, Types, End-Users in Major Region

  • POSTDATE：Jun 21, 2020
  • PAGES：217
  • REPORT CODE：GMM570439
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • This report offers an overview of the market trends, drivers, and barriers with respect to the Japan Breakthrough Therapy (BT) Designation market. It also provides a detailed overview of the market of different regions across Hokkaido, Tohoku, Kanto, Chubu, Kinki, Chugoku, Shikoku, Kyushu. The report deep analyzes type and application in Japan Breakthrough Therapy (BT) Designation market. Detailed analysis of key players, along with key growth strategies adopted by Breakthrough Therapy (BT) Designation industry, the PEST and SWOT analysis are also included. In short, the report will provide a comprehensive view of the industry's development and features.

    By Player:

    • AstraZeneca

    • BMS

    • Abbvie

    • Amgen

    • Exelixis

    • Vertex

    • Acadia

    • GlaxoSmithKline

    • Alexion

    • Regeneron

    • Takeda

    • Eisai

    • Janssen

    • Roche

    • Gilead

    • Novartis International AG

    • Merck

    • Eli Lilly

    • Pfizer

    • Boehringer Ingelheim

    • Jazz Pharmaceuticals

    • Sanofi

    By Type:

    • Oncology

    • Infectious Diseases

    • Rare Diseases

    • Autoimmune Diseases

    • Pulmonary Diseases

    • Neurological Disorders

    • Others

    By End-User:

    • Hospital

    • Clinic

    • Research Institute

    • Laboratories

    By Region:

    • Hokkaido

    • Tohoku

    • Kanto

    • Chubu

    • Kinki

    • Chugoku

    • Shikoku

    • Kyushu

  • 1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Breakthrough Therapy (BT) Designation Market

    • 1.3 Market Segment by Type

      • 1.3.1 Japan Breakthrough Therapy (BT) Designation Market Size and Growth Rate of Oncology from 2014 to 2026

      • 1.3.2 Japan Breakthrough Therapy (BT) Designation Market Size and Growth Rate of Infectious Diseases from 2014 to 2026

      • 1.3.3 Japan Breakthrough Therapy (BT) Designation Market Size and Growth Rate of Rare Diseases from 2014 to 2026

      • 1.3.4 Japan Breakthrough Therapy (BT) Designation Market Size and Growth Rate of Autoimmune Diseases from 2014 to 2026

      • 1.3.5 Japan Breakthrough Therapy (BT) Designation Market Size and Growth Rate of Pulmonary Diseases from 2014 to 2026

      • 1.3.6 Japan Breakthrough Therapy (BT) Designation Market Size and Growth Rate of Neurological Disorders from 2014 to 2026

      • 1.3.7 Japan Breakthrough Therapy (BT) Designation Market Size and Growth Rate of Others from 2014 to 2026

    • 1.4 Market Segment by Application

      • 1.4.1 Market Size and Growth Rate of Hospital

      • 1.4.2 Market Size and Growth Rate of Clinic

      • 1.4.3 Market Size and Growth Rate of Research Institute

      • 1.4.4 Market Size and Growth Rate of Laboratories

    • 1.5 Market Segment by Regions

      • 1.5.1 Hokkaido Breakthrough Therapy (BT) Designation Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.2 Tohoku Breakthrough Therapy (BT) Designation Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.3 Kanto Breakthrough Therapy (BT) Designation Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.4 Chubu Breakthrough Therapy (BT) Designation Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.5 Kinki Breakthrough Therapy (BT) Designation Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.6 Chugoku Breakthrough Therapy (BT) Designation Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.7 Shikoku Breakthrough Therapy (BT) Designation Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.8 Kyushu Breakthrough Therapy (BT) Designation Consumption Market Size and Growth Rate from 2014 to 2026

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    3 Segmentation of Breakthrough Therapy (BT) Designation Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Vendors

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Breakthrough Therapy (BT) Designation by Major Types

      • 3.4.1 Japan Breakthrough Therapy (BT) Designation Market Size and Growth Rate of Oncology from 2014 to 2026

      • 3.4.2 Japan Breakthrough Therapy (BT) Designation Market Size and Growth Rate of Infectious Diseases from 2014 to 2026

      • 3.4.3 Japan Breakthrough Therapy (BT) Designation Market Size and Growth Rate of Rare Diseases from 2014 to 2026

      • 3.4.4 Japan Breakthrough Therapy (BT) Designation Market Size and Growth Rate of Autoimmune Diseases from 2014 to 2026

      • 3.4.5 Japan Breakthrough Therapy (BT) Designation Market Size and Growth Rate of Pulmonary Diseases from 2014 to 2026

      • 3.4.6 Japan Breakthrough Therapy (BT) Designation Market Size and Growth Rate of Neurological Disorders from 2014 to 2026

      • 3.4.7 Japan Breakthrough Therapy (BT) Designation Market Size and Growth Rate of Others from 2014 to 2026

    4 Segmentation of Breakthrough Therapy (BT) Designation Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Breakthrough Therapy (BT) Designation by Major End-Users

      • 4.4.1 Market Size and Growth Rate of Breakthrough Therapy (BT) Designation in Hospital

      • 4.4.2 Market Size and Growth Rate of Breakthrough Therapy (BT) Designation in Clinic

      • 4.4.3 Market Size and Growth Rate of Breakthrough Therapy (BT) Designation in Research Institute

      • 4.4.4 Market Size and Growth Rate of Breakthrough Therapy (BT) Designation in Laboratories

    5 Market Analysis by Regions

    • 5.1 Japan Breakthrough Therapy (BT) Designation Production Analysis by Regions

    • 5.2 Japan Breakthrough Therapy (BT) Designation Consumption Analysis by Regions

    6 Hokkaido Breakthrough Therapy (BT) Designation Landscape Analysis

    • 6.1 Hokkaido Breakthrough Therapy (BT) Designation Landscape Analysis by Major Types

    • 6.2 Hokkaido Breakthrough Therapy (BT) Designation Landscape Analysis by Major End-Users

    7 Tohoku Breakthrough Therapy (BT) Designation Landscape Analysis

    • 7.1 Tohoku Breakthrough Therapy (BT) Designation Landscape Analysis by Major Types

    • 7.2 Tohoku Breakthrough Therapy (BT) Designation Landscape Analysis by Major End-Users

    8 Kanto Breakthrough Therapy (BT) Designation Landscape Analysis

    • 8.1 Kanto Breakthrough Therapy (BT) Designation Landscape Analysis by Major Types

    • 8.2 Kanto Breakthrough Therapy (BT) Designation Landscape Analysis by Major End-Users

    9 Chubu Breakthrough Therapy (BT) Designation Landscape Analysis

    • 9.1 Chubu Breakthrough Therapy (BT) Designation Landscape Analysis by Major Types

    • 9.2 Chubu Breakthrough Therapy (BT) Designation Landscape Analysis by Major End-Users

    10 Kinki Breakthrough Therapy (BT) Designation Landscape Analysis

    • 10.1 Kinki Breakthrough Therapy (BT) Designation Landscape Analysis by Major Types

    • 10.2 Kinki Breakthrough Therapy (BT) Designation Landscape Analysis by Major End-Users

    11 Chugoku Breakthrough Therapy (BT) Designation Landscape Analysis

    • 11.1 Chugoku Breakthrough Therapy (BT) Designation Landscape Analysis by Major Types

    • 11.2 Chugoku Breakthrough Therapy (BT) Designation Landscape Analysis by Major End-Users

    12 Shikoku Breakthrough Therapy (BT) Designation Landscape Analysis

    • 12.1 Shikoku Breakthrough Therapy (BT) Designation Landscape Analysis by Major Types

    • 12.2 Shikoku Breakthrough Therapy (BT) Designation Landscape Analysis by Major End-Users

    13 Kyushu Breakthrough Therapy (BT) Designation Landscape Analysis

    • 13.1 Kyushu Breakthrough Therapy (BT) Designation Landscape Analysis by Major Types

    • 13.2 Kyushu Breakthrough Therapy (BT) Designation Landscape Analysis by Major End-Users

    14 Major Players Profiles

    • 14.1 AstraZeneca

      • 14.1.1 AstraZeneca Company Profile and Recent Development

      • 14.1.2 AstraZeneca Market Performance

      • 14.1.3 AstraZeneca Product and Service Introduction

    • 14.2 BMS

      • 14.2.1 BMS Company Profile and Recent Development

      • 14.2.2 BMS Market Performance

      • 14.2.3 BMS Product and Service Introduction

    • 14.3 Abbvie

      • 14.3.1 Abbvie Company Profile and Recent Development

      • 14.3.2 Abbvie Market Performance

      • 14.3.3 Abbvie Product and Service Introduction

    • 14.4 Amgen

      • 14.4.1 Amgen Company Profile and Recent Development

      • 14.4.2 Amgen Market Performance

      • 14.4.3 Amgen Product and Service Introduction

    • 14.5 Exelixis

      • 14.5.1 Exelixis Company Profile and Recent Development

      • 14.5.2 Exelixis Market Performance

      • 14.5.3 Exelixis Product and Service Introduction

    • 14.6 Vertex

      • 14.6.1 Vertex Company Profile and Recent Development

      • 14.6.2 Vertex Market Performance

      • 14.6.3 Vertex Product and Service Introduction

    • 14.7 Acadia

      • 14.7.1 Acadia Company Profile and Recent Development

      • 14.7.2 Acadia Market Performance

      • 14.7.3 Acadia Product and Service Introduction

    • 14.8 GlaxoSmithKline

      • 14.8.1 GlaxoSmithKline Company Profile and Recent Development

      • 14.8.2 GlaxoSmithKline Market Performance

      • 14.8.3 GlaxoSmithKline Product and Service Introduction

    • 14.9 Alexion

      • 14.9.1 Alexion Company Profile and Recent Development

      • 14.9.2 Alexion Market Performance

      • 14.9.3 Alexion Product and Service Introduction

    • 14.10 Regeneron

      • 14.10.1 Regeneron Company Profile and Recent Development

      • 14.10.2 Regeneron Market Performance

      • 14.10.3 Regeneron Product and Service Introduction

    • 14.11 Takeda

      • 14.11.1 Takeda Company Profile and Recent Development

      • 14.11.2 Takeda Market Performance

      • 14.11.3 Takeda Product and Service Introduction

    • 14.12 Eisai

      • 14.12.1 Eisai Company Profile and Recent Development

      • 14.12.2 Eisai Market Performance

      • 14.12.3 Eisai Product and Service Introduction

    • 14.13 Janssen

      • 14.13.1 Janssen Company Profile and Recent Development

      • 14.13.2 Janssen Market Performance

      • 14.13.3 Janssen Product and Service Introduction

    • 14.14 Roche

      • 14.14.1 Roche Company Profile and Recent Development

      • 14.14.2 Roche Market Performance

      • 14.14.3 Roche Product and Service Introduction

    • 14.15 Gilead

      • 14.15.1 Gilead Company Profile and Recent Development

      • 14.15.2 Gilead Market Performance

      • 14.15.3 Gilead Product and Service Introduction

    • 14.16 Novartis International AG

      • 14.16.1 Novartis International AG Company Profile and Recent Development

      • 14.16.2 Novartis International AG Market Performance

      • 14.16.3 Novartis International AG Product and Service Introduction

    • 14.17 Merck

      • 14.17.1 Merck Company Profile and Recent Development

      • 14.17.2 Merck Market Performance

      • 14.17.3 Merck Product and Service Introduction

    • 14.18 Eli Lilly

      • 14.18.1 Eli Lilly Company Profile and Recent Development

      • 14.18.2 Eli Lilly Market Performance

      • 14.18.3 Eli Lilly Product and Service Introduction

    • 14.19 Pfizer

      • 14.19.1 Pfizer Company Profile and Recent Development

      • 14.19.2 Pfizer Market Performance

      • 14.19.3 Pfizer Product and Service Introduction

    • 14.20 Boehringer Ingelheim

      • 14.20.1 Boehringer Ingelheim Company Profile and Recent Development

      • 14.20.2 Boehringer Ingelheim Market Performance

      • 14.20.3 Boehringer Ingelheim Product and Service Introduction

    • 14.21 Jazz Pharmaceuticals

      • 14.21.1 Jazz Pharmaceuticals Company Profile and Recent Development

      • 14.21.2 Jazz Pharmaceuticals Market Performance

      • 14.21.3 Jazz Pharmaceuticals Product and Service Introduction

    • 14.22 Sanofi

      • 14.22.1 Sanofi Company Profile and Recent Development

      • 14.22.2 Sanofi Market Performance

      • 14.22.3 Sanofi Product and Service Introduction

     

    The List of Tables and Figures (Totals 123 Figures and 141 Tables)

    • Figure Japan Breakthrough Therapy (BT) Designation Market Size and Growth Rate of Oncology from 2014 to 2026

    • Figure Japan Breakthrough Therapy (BT) Designation Market Size and Growth Rate of Infectious Diseases from 2014 to 2026

    • Figure Japan Breakthrough Therapy (BT) Designation Market Size and Growth Rate of Rare Diseases from 2014 to 2026

    • Figure Japan Breakthrough Therapy (BT) Designation Market Size and Growth Rate of Autoimmune Diseases from 2014 to 2026

    • Figure Japan Breakthrough Therapy (BT) Designation Market Size and Growth Rate of Pulmonary Diseases from 2014 to 2026

    • Figure Japan Breakthrough Therapy (BT) Designation Market Size and Growth Rate of Neurological Disorders from 2014 to 2026

    • Figure Japan Breakthrough Therapy (BT) Designation Market Size and Growth Rate of Others from 2014 to 2026

    • Figure Market Share by Type in 2014

    • Figure Market Share by Type in 2018

    • Figure Market Share by Type in 2026

    • Figure Market Size and Growth Rate of Hospital

    • Figure Market Size and Growth Rate of Clinic

    • Figure Market Size and Growth Rate of Research Institute

    • Figure Market Size and Growth Rate of Laboratories

    • Figure Market Share by End-User in 2014

    • Figure Market Share by End-User in 2018

    • Figure Market Share by End-User in 2026

    • Figure Hokkaido Breakthrough Therapy (BT) Designation Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Tohoku Breakthrough Therapy (BT) Designation Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Kanto Breakthrough Therapy (BT) Designation Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Chubu Breakthrough Therapy (BT) Designation Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Kinki Breakthrough Therapy (BT) Designation Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Chugoku Breakthrough Therapy (BT) Designation Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Shikoku Breakthrough Therapy (BT) Designation Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Kyushu Breakthrough Therapy (BT) Designation Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Development Trends and Industry Dynamics of Breakthrough Therapy (BT) Designation Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 3 Players in 2018

    • Figure Market Share of TOP 5 Players in 2018

    • Figure Market Share of TOP 6 Players from 2014 to 2019

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Table Specifications of Different Types of Breakthrough Therapy (BT) Designation

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Breakthrough Therapy (BT) Designation by Different Types from 2014 to 2026

    • Table Consumption Share of Breakthrough Therapy (BT) Designation by Different Types from 2014 to 2026

    • Figure Japan Breakthrough Therapy (BT) Designation Market Size and Growth Rate of Oncology from 2014 to 2026

    • Figure Japan Breakthrough Therapy (BT) Designation Market Size and Growth Rate of Infectious Diseases from 2014 to 2026

    • Figure Japan Breakthrough Therapy (BT) Designation Market Size and Growth Rate of Rare Diseases from 2014 to 2026

    • Figure Japan Breakthrough Therapy (BT) Designation Market Size and Growth Rate of Autoimmune Diseases from 2014 to 2026

    • Figure Japan Breakthrough Therapy (BT) Designation Market Size and Growth Rate of Pulmonary Diseases from 2014 to 2026

    • Figure Japan Breakthrough Therapy (BT) Designation Market Size and Growth Rate of Neurological Disorders from 2014 to 2026

    • Figure Japan Breakthrough Therapy (BT) Designation Market Size and Growth Rate of Others from 2014 to 2026

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Table Consumption of Breakthrough Therapy (BT) Designation by Different End-Users from 2014 to 2026

    • Table Consumption Share of Breakthrough Therapy (BT) Designation by Different End-Users from 2014 to 2026

    • Figure Market Size and Growth Rate of Hospital

    • Figure Market Size and Growth Rate of Clinic

    • Figure Market Size and Growth Rate of Research Institute

    • Figure Market Size and Growth Rate of Laboratories

    • Table Japan Breakthrough Therapy (BT) Designation Production by Regions

    • Table Japan Breakthrough Therapy (BT) Designation Production Share by Regions

    • Figure Japan Breakthrough Therapy (BT) Designation Production Share by Regions in 2014

    • Figure Japan Breakthrough Therapy (BT) Designation Production Share by Regions in 2018

    • Figure Japan Breakthrough Therapy (BT) Designation Production Share by Regions in 2026

    • Table Japan Breakthrough Therapy (BT) Designation Consumption by Regions

    • Table Japan Breakthrough Therapy (BT) Designation Consumption Share by Regions

    • Figure Japan Breakthrough Therapy (BT) Designation Consumption Share by Regions in 2014

    • Figure Japan Breakthrough Therapy (BT) Designation Consumption Share by Regions in 2018

    • Figure Japan Breakthrough Therapy (BT) Designation Consumption Share by Regions in 2026

    • Table Hokkaido Breakthrough Therapy (BT) Designation Consumption by Types from 2014 to 2026

    • Table Hokkaido Breakthrough Therapy (BT) Designation Consumption Share by Types from 2014 to 2026

    • Figure Hokkaido Breakthrough Therapy (BT) Designation Consumption Share by Types in 2014

    • Figure Hokkaido Breakthrough Therapy (BT) Designation Consumption Share by Types in 2018

    • Figure Hokkaido Breakthrough Therapy (BT) Designation Consumption Share by Types in 2026

    • Table Hokkaido Breakthrough Therapy (BT) Designation Consumption by End-Users from 2014 to 2026

    • Table Hokkaido Breakthrough Therapy (BT) Designation Consumption Share by End-Users from 2014 to 2026

    • Figure Hokkaido Breakthrough Therapy (BT) Designation Consumption Share by End-Users in 2014

    • Figure Hokkaido Breakthrough Therapy (BT) Designation Consumption Share by End-Users in 2018

    • Figure Hokkaido Breakthrough Therapy (BT) Designation Consumption Share by End-Users in 2026

    • Table Tohoku Breakthrough Therapy (BT) Designation Consumption by Types from 2014 to 2026

    • Table Tohoku Breakthrough Therapy (BT) Designation Consumption Share by Types from 2014 to 2026

    • Figure Tohoku Breakthrough Therapy (BT) Designation Consumption Share by Types in 2014

    • Figure Tohoku Breakthrough Therapy (BT) Designation Consumption Share by Types in 2018

    • Figure Tohoku Breakthrough Therapy (BT) Designation Consumption Share by Types in 2026

    • Table Tohoku Breakthrough Therapy (BT) Designation Consumption by End-Users from 2014 to 2026

    • Table Tohoku Breakthrough Therapy (BT) Designation Consumption Share by End-Users from 2014 to 2026

    • Figure Tohoku Breakthrough Therapy (BT) Designation Consumption Share by End-Users in 2014

    • Figure Tohoku Breakthrough Therapy (BT) Designation Consumption Share by End-Users in 2018

    • Figure Tohoku Breakthrough Therapy (BT) Designation Consumption Share by End-Users in 2026

    • Table Kanto Breakthrough Therapy (BT) Designation Consumption by Types from 2014 to 2026

    • Table Kanto Breakthrough Therapy (BT) Designation Consumption Share by Types from 2014 to 2026

    • Figure Kanto Breakthrough Therapy (BT) Designation Consumption Share by Types in 2014

    • Figure Kanto Breakthrough Therapy (BT) Designation Consumption Share by Types in 2018

    • Figure Kanto Breakthrough Therapy (BT) Designation Consumption Share by Types in 2026

    • Table Kanto Breakthrough Therapy (BT) Designation Consumption by End-Users from 2014 to 2026

    • Table Kanto Breakthrough Therapy (BT) Designation Consumption Share by End-Users from 2014 to 2026

    • Figure Kanto Breakthrough Therapy (BT) Designation Consumption Share by End-Users in 2014

    • Figure Kanto Breakthrough Therapy (BT) Designation Consumption Share by End-Users in 2018

    • Figure Kanto Breakthrough Therapy (BT) Designation Consumption Share by End-Users in 2026

    • Table Chubu Breakthrough Therapy (BT) Designation Consumption by Types from 2014 to 2026

    • Table Chubu Breakthrough Therapy (BT) Designation Consumption Share by Types from 2014 to 2026

    • Figure Chubu Breakthrough Therapy (BT) Designation Consumption Share by Types in 2014

    • Figure Chubu Breakthrough Therapy (BT) Designation Consumption Share by Types in 2018

    • Figure Chubu Breakthrough Therapy (BT) Designation Consumption Share by Types in 2026

    • Table Chubu Breakthrough Therapy (BT) Designation Consumption by End-Users from 2014 to 2026

    • Table Chubu Breakthrough Therapy (BT) Designation Consumption Share by End-Users from 2014 to 2026

    • Figure Chubu Breakthrough Therapy (BT) Designation Consumption Share by End-Users in 2014

    • Figure Chubu Breakthrough Therapy (BT) Designation Consumption Share by End-Users in 2018

    • Figure Chubu Breakthrough Therapy (BT) Designation Consumption Share by End-Users in 2026

    • Table Kinki Breakthrough Therapy (BT) Designation Consumption by Types from 2014 to 2026

    • Table Kinki Breakthrough Therapy (BT) Designation Consumption Share by Types from 2014 to 2026

    • Figure Kinki Breakthrough Therapy (BT) Designation Consumption Share by Types in 2014

    • Figure Kinki Breakthrough Therapy (BT) Designation Consumption Share by Types in 2018

    • Figure Kinki Breakthrough Therapy (BT) Designation Consumption Share by Types in 2026

    • Table Kinki Breakthrough Therapy (BT) Designation Consumption by End-Users from 2014 to 2026

    • Table Kinki Breakthrough Therapy (BT) Designation Consumption Share by End-Users from 2014 to 2026

    • Figure Kinki Breakthrough Therapy (BT) Designation Consumption Share by End-Users in 2014

    • Figure Kinki Breakthrough Therapy (BT) Designation Consumption Share by End-Users in 2018

    • Figure Kinki Breakthrough Therapy (BT) Designation Consumption Share by End-Users in 2026

    • Table Chugoku Breakthrough Therapy (BT) Designation Consumption by Types from 2014 to 2026

    • Table Chugoku Breakthrough Therapy (BT) Designation Consumption Share by Types from 2014 to 2026

    • Figure Chugoku Breakthrough Therapy (BT) Designation Consumption Share by Types in 2014

    • Figure Chugoku Breakthrough Therapy (BT) Designation Consumption Share by Types in 2018

    • Figure Chugoku Breakthrough Therapy (BT) Designation Consumption Share by Types in 2026

    • Table Chugoku Breakthrough Therapy (BT) Designation Consumption by End-Users from 2014 to 2026

    • Table Chugoku Breakthrough Therapy (BT) Designation Consumption Share by End-Users from 2014 to 2026

    • Figure Chugoku Breakthrough Therapy (BT) Designation Consumption Share by End-Users in 2014

    • Figure Chugoku Breakthrough Therapy (BT) Designation Consumption Share by End-Users in 2018

    • Figure Chugoku Breakthrough Therapy (BT) Designation Consumption Share by End-Users in 2026

    • Table Shikoku Breakthrough Therapy (BT) Designation Consumption by Types from 2014 to 2026

    • Table Shikoku Breakthrough Therapy (BT) Designation Consumption Share by Types from 2014 to 2026

    • Figure Shikoku Breakthrough Therapy (BT) Designation Consumption Share by Types in 2014

    • Figure Shikoku Breakthrough Therapy (BT) Designation Consumption Share by Types in 2018

    • Figure Shikoku Breakthrough Therapy (BT) Designation Consumption Share by Types in 2026

    • Table Shikoku Breakthrough Therapy (BT) Designation Consumption by End-Users from 2014 to 2026

    • Table Shikoku Breakthrough Therapy (BT) Designation Consumption Share by End-Users from 2014 to 2026

    • Figure Shikoku Breakthrough Therapy (BT) Designation Consumption Share by End-Users in 2014

    • Figure Shikoku Breakthrough Therapy (BT) Designation Consumption Share by End-Users in 2018

    • Figure Shikoku Breakthrough Therapy (BT) Designation Consumption Share by End-Users in 2026

    • Table Kyushu Breakthrough Therapy (BT) Designation Consumption by Types from 2014 to 2026

    • Table Kyushu Breakthrough Therapy (BT) Designation Consumption Share by Types from 2014 to 2026

    • Figure Kyushu Breakthrough Therapy (BT) Designation Consumption Share by Types in 2014

    • Figure Kyushu Breakthrough Therapy (BT) Designation Consumption Share by Types in 2018

    • Figure Kyushu Breakthrough Therapy (BT) Designation Consumption Share by Types in 2026

    • Table Kyushu Breakthrough Therapy (BT) Designation Consumption by End-Users from 2014 to 2026

    • Table Kyushu Breakthrough Therapy (BT) Designation Consumption Share by End-Users from 2014 to 2026

    • Figure Kyushu Breakthrough Therapy (BT) Designation Consumption Share by End-Users in 2014

    • Figure Kyushu Breakthrough Therapy (BT) Designation Consumption Share by End-Users in 2018

    • Figure Kyushu Breakthrough Therapy (BT) Designation Consumption Share by End-Users in 2026

    • Table Company Profile and Development Status of AstraZeneca

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of AstraZeneca

    • Figure Sales and Growth Rate Analysis of AstraZeneca

    • Figure Revenue and Market Share Analysis of AstraZeneca

    • Table Product and Service Introduction of AstraZeneca

    • Table Company Profile and Development Status of BMS

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of BMS

    • Figure Sales and Growth Rate Analysis of BMS

    • Figure Revenue and Market Share Analysis of BMS

    • Table Product and Service Introduction of BMS

    • Table Company Profile and Development Status of Abbvie

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Abbvie

    • Figure Sales and Growth Rate Analysis of Abbvie

    • Figure Revenue and Market Share Analysis of Abbvie

    • Table Product and Service Introduction of Abbvie

    • Table Company Profile and Development Status of Amgen

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Amgen

    • Figure Sales and Growth Rate Analysis of Amgen

    • Figure Revenue and Market Share Analysis of Amgen

    • Table Product and Service Introduction of Amgen

    • Table Company Profile and Development Status of Exelixis

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Exelixis

    • Figure Sales and Growth Rate Analysis of Exelixis

    • Figure Revenue and Market Share Analysis of Exelixis

    • Table Product and Service Introduction of Exelixis

    • Table Company Profile and Development Status of Vertex

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Vertex

    • Figure Sales and Growth Rate Analysis of Vertex

    • Figure Revenue and Market Share Analysis of Vertex

    • Table Product and Service Introduction of Vertex

    • Table Company Profile and Development Status of Acadia

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Acadia

    • Figure Sales and Growth Rate Analysis of Acadia

    • Figure Revenue and Market Share Analysis of Acadia

    • Table Product and Service Introduction of Acadia

    • Table Company Profile and Development Status of GlaxoSmithKline

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of GlaxoSmithKline

    • Figure Sales and Growth Rate Analysis of GlaxoSmithKline

    • Figure Revenue and Market Share Analysis of GlaxoSmithKline

    • Table Product and Service Introduction of GlaxoSmithKline

    • Table Company Profile and Development Status of Alexion

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Alexion

    • Figure Sales and Growth Rate Analysis of Alexion

    • Figure Revenue and Market Share Analysis of Alexion

    • Table Product and Service Introduction of Alexion

    • Table Company Profile and Development Status of Regeneron

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Regeneron

    • Figure Sales and Growth Rate Analysis of Regeneron

    • Figure Revenue and Market Share Analysis of Regeneron

    • Table Product and Service Introduction of Regeneron

    • Table Company Profile and Development Status of Takeda

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Takeda

    • Figure Sales and Growth Rate Analysis of Takeda

    • Figure Revenue and Market Share Analysis of Takeda

    • Table Product and Service Introduction of Takeda

    • Table Company Profile and Development Status of Eisai

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Eisai

    • Figure Sales and Growth Rate Analysis of Eisai

    • Figure Revenue and Market Share Analysis of Eisai

    • Table Product and Service Introduction of Eisai

    • Table Company Profile and Development Status of Janssen

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Janssen

    • Figure Sales and Growth Rate Analysis of Janssen

    • Figure Revenue and Market Share Analysis of Janssen

    • Table Product and Service Introduction of Janssen

    • Table Company Profile and Development Status of Roche

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Roche

    • Figure Sales and Growth Rate Analysis of Roche

    • Figure Revenue and Market Share Analysis of Roche

    • Table Product and Service Introduction of Roche

    • Table Company Profile and Development Status of Gilead

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Gilead

    • Figure Sales and Growth Rate Analysis of Gilead

    • Figure Revenue and Market Share Analysis of Gilead

    • Table Product and Service Introduction of Gilead

    • Table Company Profile and Development Status of Novartis International AG

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Novartis International AG

    • Figure Sales and Growth Rate Analysis of Novartis International AG

    • Figure Revenue and Market Share Analysis of Novartis International AG

    • Table Product and Service Introduction of Novartis International AG

    • Table Company Profile and Development Status of Merck

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Merck

    • Figure Sales and Growth Rate Analysis of Merck

    • Figure Revenue and Market Share Analysis of Merck

    • Table Product and Service Introduction of Merck

    • Table Company Profile and Development Status of Eli Lilly

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Eli Lilly

    • Figure Sales and Growth Rate Analysis of Eli Lilly

    • Figure Revenue and Market Share Analysis of Eli Lilly

    • Table Product and Service Introduction of Eli Lilly

    • Table Company Profile and Development Status of Pfizer

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Pfizer

    • Figure Sales and Growth Rate Analysis of Pfizer

    • Figure Revenue and Market Share Analysis of Pfizer

    • Table Product and Service Introduction of Pfizer

    • Table Company Profile and Development Status of Boehringer Ingelheim

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Boehringer Ingelheim

    • Figure Sales and Growth Rate Analysis of Boehringer Ingelheim

    • Figure Revenue and Market Share Analysis of Boehringer Ingelheim

    • Table Product and Service Introduction of Boehringer Ingelheim

    • Table Company Profile and Development Status of Jazz Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Jazz Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Jazz Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Jazz Pharmaceuticals

    • Table Product and Service Introduction of Jazz Pharmaceuticals

    • Table Company Profile and Development Status of Sanofi

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Sanofi

    • Figure Sales and Growth Rate Analysis of Sanofi

    • Figure Revenue and Market Share Analysis of Sanofi

    • Table Product and Service Introduction of Sanofi

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US